Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Patients With Essential Hypertension

This study has been completed.
Information provided by (Responsible Party):
Novartis Identifier:
First received: April 24, 2008
Last updated: November 15, 2016
Last verified: November 2012
This study will test the safety of the combination of aliskiren/amlodipine/hydrochlorothiazide in patients with essential hypertension

Condition Intervention Phase
Essential Hypertension
Drug: aliskiren /amlodipine/hydrochlorothiazide
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 28 to 54-week, Open-label, Multicenter Study to Assess the Long-term Safety and Tolerability of the Combination of Aliskiren / Amlodipine / Hydrochlorothiazide in Patients With Essential Hypertension

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • To assess the long term safety of the combination of aliskiren /amlodipine / hydrochlorothiazide in patients with essential hypertension over 28 weeks to 54 weeks of treatment. [ Time Frame: 28 weeks ]

Secondary Outcome Measures:
  • To assess the long-term blood pressure lowering (msDBP and msSBP) efficacy of the combination of aliskiren / amlodipine / hydrochlorothiazide in patients with essential hypertension [ Time Frame: 0 ]
  • To evaluate the proportion of patients achieving the blood pressure control target of < 140/90 mmHg at the end of the study. [ Time Frame: 0 ]

Enrollment: 564
Study Start Date: June 2008
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
aliskiren 300/mg + amlodipine 10 mg + hydrochlorothiazide
Drug: aliskiren /amlodipine/hydrochlorothiazide
1x aliskiren/amlodipine/hydrochlorothiazide


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Outpatients 18 years of age or older
  • Male or female patients are eligible.
  • msDBP & msSBP Requirements:

    • For newly diagnosed/untreated patients, msDBP ≥ 100 and < 120 mmHg, and/or msSBP ≥ 160 and < 200 mmHg at Visit 1 and Visit 2.
    • For previously treated patients, msDBP ≥ 100 and < 120 mmHg, and/or msSBP ≥ 160 and < 200 mmHg at Visit 2, Visit 3, or Visit 4.
  • For patients requiring tapering off their previous antihypertensive medication, they must meet the above criteria and completely discontinue all antihypertensive treatment prior to entering the treatment phase of the study.
  • Patients who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written informed consent).

Exclusion Criteria:

  • Inability to discontinue all prior antihypertensive medications safely for a period of 1 week to 4 weeks as required by the protocol.
  • Patients on three antihypertensive drugs with msDBP ≥ 110 mmHg and/or msSBP ≥ 180 mmHg at Visit 1.
  • Patients on four or more antihypertensive drugs at Visit 1.
  • Patients with an msSBP ≥ 200 and msDBP ≥ 120 mmHg anytime during the washout period of the study Visit 1-4 must be discontinued from the study.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>= 5 mIU/mL).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00667719

United States, Texas
Investigative Site
Houston, Texas, United States
Investigative Site
Belgium, Belgium
Investigative Site
Egypt, Egypt
Investigative Site
Germany, Germany
Investigative Site
Poland, Poland
Investigative Site
Slovakia, Slovakia
Investigative Site
Spain, Spain
Investigative Site
Turkey, Turkey
Sponsors and Collaborators
Study Chair: Novartis Novartis
  More Information

Additional Information:
Responsible Party: Novartis Identifier: NCT00667719     History of Changes
Other Study ID Numbers: CSAH100A2301
Study First Received: April 24, 2008
Last Updated: November 15, 2016

Keywords provided by Novartis:
essential hypertension
high blood pressure

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Natriuretic Agents
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors processed this record on May 25, 2017